98 related articles for article (PubMed ID: 21993737)
1. France toughens conflict rules.
Butler D
Nature; 2011 Oct; 478(7368):169. PubMed ID: 21993737
[No Abstract] [Full Text] [Related]
2. European drug regulator is being investigated by fraud agency.
Kmietowicz Z
BMJ; 2011 Nov; 343():d7283. PubMed ID: 22077089
[No Abstract] [Full Text] [Related]
3. In the wake of the Mediator scandal: some progress in France, but apathy at the European level.
Prescrire Int; 2012 Apr; 21(126):110. PubMed ID: 22515143
[No Abstract] [Full Text] [Related]
4. Top adviser at the European Medicines Agency quits suddenly.
Benkimoun P
BMJ; 2012 Apr; 344():e2641. PubMed ID: 22496308
[No Abstract] [Full Text] [Related]
5. French law to make conflict of interest disclosure mandatory.
Louët S
Nat Med; 2011 Sep; 17(9):1026. PubMed ID: 21900902
[No Abstract] [Full Text] [Related]
6. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
7. How to avoid future Vioxx-type scandals.
Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108
[TBL] [Abstract][Full Text] [Related]
8. [Mediator, the police of the medication in question].
Mauduit L
Soins; 2011 Apr; (754):6. PubMed ID: 21574303
[No Abstract] [Full Text] [Related]
9. Conflicts of interest within the French regulatory agency: more progress needed.
Prescrire Int; 2010 Aug; 19(108):186-8. PubMed ID: 20939461
[TBL] [Abstract][Full Text] [Related]
10. [The French are wary of their drugs].
Nau JY
Rev Med Suisse; 2011 May; 7(296):1170-1. PubMed ID: 21728251
[No Abstract] [Full Text] [Related]
11. Making medicines safer--the need for an independent drug safety board.
Wood AJ; Stein CM; Woosley R
N Engl J Med; 1998 Dec; 339(25):1851-4. PubMed ID: 9854125
[No Abstract] [Full Text] [Related]
12. European Medicines Agency tightens rules on conflict of interest.
Cohen D
BMJ; 2010 Oct; 341():c5902. PubMed ID: 20959306
[No Abstract] [Full Text] [Related]
13. Marketing off-label uses to physicians: FDA's draft (mis)guidance.
Gass A; Wilson J
Am J Bioeth; 2008 Mar; 8(3):1-3. PubMed ID: 18570084
[No Abstract] [Full Text] [Related]
14. Need to strike balance with industry-academia rules.
Leuchter A; Levey GS
Nature; 2007 Oct; 449(7163):658. PubMed ID: 17928837
[No Abstract] [Full Text] [Related]
15. Food and Drug Administration regulation and evaluation of vaccines.
Marshall V; Baylor NW
Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
[TBL] [Abstract][Full Text] [Related]
16. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
17. Managing conflicts of interest: a survival guide for biotechs.
Werner MJ; Price E
Nat Biotechnol; 2007 Feb; 25(2):161-3. PubMed ID: 17375384
[TBL] [Abstract][Full Text] [Related]
18. Industry reneges on postmarketing trial commitments.
Bouchie A
Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
[No Abstract] [Full Text] [Related]
19. The marketplace can't give us the drug safety data we need.
Avorn J
MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
[No Abstract] [Full Text] [Related]
20. Challenging special interest groups: whistleblowers may help. Help them!
Braillon A
Psychother Psychosom; 2011; 80(2):116-7. PubMed ID: 21212718
[No Abstract] [Full Text] [Related]
[Next] [New Search]
